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ABSTRACT
Objectives To determine the feasibility of conducting 
a full- scale randomised controlled trial (RCT) of the 
effectiveness and cost- effectiveness of a self- aligning 
prosthetic ankle- foot compared with a standard prosthetic 
ankle- foot.
Design Multicentre parallel group feasibility RCT.
Setting Five prosthetics centres in England recruiting 
from July 2018 to August 2019.
Participants Adults aged ≥50 years with a vascular- 
related or non- traumatic transtibial amputation for 1 year 
or longer, categorised as having ‘limited community 
mobility’ and using a non- self- aligning ankle- foot.
Intervention Participants were randomised into one of 
two groups for 12 weeks: self- aligning prosthetic ankle- 
foot or existing non- self- aligning prosthetic ankle- foot.
Outcomes Feasibility measures: recruitment, consent and 
retention rates; and completeness of questionnaire and 
clinical assessment datasets across multiple time points. 
Feasibility of collecting daily activity data with wearable 
technology and health resource use data with a bespoke 
questionnaire.
Results Fifty- five participants were randomised (61% 
of the target 90 participants): n=27 self- aligning ankle- 
foot group, n=28 non- self- aligning ankle- foot group. 
Fifty- one participants were included in the final analysis 
(71% of the target number of participants). The consent 
rate and retention at final follow- up were 86% and 93%, 
respectively. The average recruitment rate was 1.25 
participants/site/month (95% CI 0.39 to 2.1). Completeness 
of questionnaires ranged from 89%–94%, and clinical 
assessments were 92%–95%, including the activity 
monitor data. The average completion rates for the EQ- 5D- 
5L and bespoke resource use questionnaire were 93% and 
63%, respectively.
Conclusions This feasibility trial recruited and retained 
participants who were categorised as having ‘limited 
community mobility’ following a transtibial amputation. 
The high retention rate of 93% indicated the trial was 
acceptable to participants and feasible to deliver as a 
full- scale RCT. The findings support a future, fully powered 
evaluation of the effectiveness and cost- effectiveness 
of a self- aligning prosthetic ankle- foot compared with a 
standard non- self- aligning version with some adjustments 
to the trial design and delivery.
Trial registration number ISRCTN15043643.
INTRODUCTION
In the UK, there are approximately 6000 new 
referrals to prosthetics services every year. 
Most of these referrals are patients aged over 
50 years who have had an amputation at the 
transtibial (below- knee) level.1 The majority 
of lower limb amputations result from long- 
term diabetes mellitus, coronary and periph-
eral vascular diseases.2 3 Consequently, most 
new referrals for a prosthesis involve older 
adults who have other health comorbidities 
and who are categorised as having ‘limited 
community mobility’. These patients are an 
under- researched group, with few studies 
focused on their mobility with a prosthesis.
Strengths and limitations of this study
 ► This was one of few clinical trials investigating 
ankle- foot prostheses within prosthetics services 
in the UK. The study design is a multicentre, ran-
domised controlled trial in an under- researched clin-
ical population involving prosthetics.
 ► The completeness of subjective and objective as-
sessment measures, administered in a clinical set-
ting and via post, was high.
 ► Feasibility and acceptability were ascertained with 
quantitative and trial procedure data.
 ► Recruitment was lower and slower than anticipated, 
but the ability to retain participants was high.
 ► Effectiveness and cost- effectiveness of a self- 
aligning ankle- foot will need to be established in a 
definitive full- scale trial.
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Many factors determine the type of prosthesis that a 
patient receives, such as estimation of patient outcomes 
and goals, and the healthcare budget.4 A Cochrane review 
reported that there was insufficient evidence from robust 
studies to support the ‘overall superiority of any individual 
type of prosthetic ankle- foot mechanism’.5 There are also 
no standardised criteria for the prescription of ankle- 
foot prostheses. Practice varies across UK centres and is 
frequently cost driven. Subsequently, the majority of older 
people with a transtibial amputation receive a standard, 
non- self- aligning ankle- foot, such as the non- articulated 
solid ankle cushioned heel (SACH), uniaxial or multiaxial 
prosthetic foot. These prosthetic ankle- feet have limited 
functionality. The SACH foot has a solid ‘ankle’ that does 
not allow any movement. The uniaxial ankle- foot is only 
capable of moving about a single axis with some ankle 
dorsi- and plantar- flexion; the multiaxial ankle- foot can 
rotate about multiple axes, allowing ankle dorsi- and 
plantar- flexion and eversion–inversion. The elastic recoil 
to return to a plantigrade position makes the uniaxial 
and multiaxial ankle- feet unable to self- align to inclined 
surfaces, making these feet more suitable for standing or 
walking on level ground. This requires the user to make 
compensatory actions at proximal joints (compensations 
at the hip bilaterally and intact knee of the affected limb) 
and at the intact ankle to achieve stability with a ‘foot flat’ 
position when walking on slopes.6 7 These actions result 
in greater asymmetry between the two limbs and increase 
the metabolic requirements of walking.6 This can make 
walking more difficult and tiring. Our public involvement 
members reported that a poorly functioning prosthesis 
can contribute to sedentary behaviour, pain and more 
frequent visits to prosthetics centres and other healthcare 
services, which may lead to disuse and poorer quality of 
life. Therefore, identifying a more functionally suitable 
prosthesis could benefit patients in meaningful ways 
following amputation.
A ‘family’ of prosthetic ankle- feet that use a hydraulic 
mechanism to self- align to sloped surfaces have been 
designed to attenuate many of the burdens associated 
with standard, non- self- aligning ankle- feet. These pros-
thetic ankle- feet have been designed for users of varying 
ability (more active users, K3–K4 classification) and 
also for users categorised as having ‘limited community 
mobility’ (K2 users).8 The hydraulic mechanism allows the 
prosthetic ankle- foot to self- align to sloped surfaces (due 
to ground reaction forces) and remain in a dorsiflexed 
position throughout the swing phase. This can improve 
ground clearance and secure the biological knee, which 
is important for falls prevention.9 Previous laboratory- 
based studies reported that a self- aligning ankle- foot 
reduced residuum- socket interface pressures in active 
users,10 which could alleviate pain in the residuum longer 
term, improved walking11 and enhanced quality of life12 13 
in users with lower activity levels.
More functional prostheses may improve patient func-
tion and mobility following a lower limb amputation.14 
However, the effects of a self- aligning prosthesis have not 
been evaluated with robust randomised controlled trials 
(RCTs) in a community setting. In particular, there is a 
lack of research involving participants who have had a 
non- traumatic (eg, vascular- related) amputation. A self- 
aligning ankle- foot is more expensive than a non- self- 
aligning version by approximately £900 for the K2- user 
version (at 2020 UK prices) with variations in price across 
manufacturers. However, the potential patient bene-
fits, such as improved mobility, better quality of life and 
reduced falls, could offset future healthcare and socio-
economic costs.
There is a need for an RCT of the effectiveness and cost- 
effectiveness of a self- aligning prosthetic ankle- foot for 
older patients, with a vascular- related or non- traumatic 
transtibial amputation, compared with a standard, non- 
self- aligning ankle- foot. The STEPFORWARD study used 
a mixed- methods approach to determine feasibility of 
conducting such a study. A feasibility study was considered 
important in advance of a full- scale RCT given the lack of 
large community- based RCTs in this field. A full- scale trial 
will be powered appropriately to detect a difference in 
the primary outcome between the two trial arms (and as 
such has a sample size large enough to answer a research 
question on intervention effectiveness). A feasibility 
study addresses the question of whether a specific study 
can be done, whether it should proceed and, if so, how.15 
It is not designed to address the question of whether an 
intervention works. This article reports the feasibility as 
determined by the quantitative data, which was assessed 
according to: (1) participant recruitment, including time 
to recruit, consent and retention rates and adverse events 
(AEs); (2) completeness of data across multiple time 
points, including health economics data while piloting a 
bespoke health resource use questionnaire and (3) day- 
to- day activity measured with wearable technology. The 
findings from this work could be relevant to clinical prac-
titioners, researchers and policy- makers.
METHODS
Study design and participants
The STEPFORWARD trial was a multicentre, parallel 
group, randomised controlled feasibility trial to assess 
the possibility of conducting a full- scale RCT in the 
future, which would be adequately powered to answer the 
primary research question. The full study protocol, with 
detailed inclusion/exclusion criteria and recruitment/
screening pathways, has been published16 and is briefly 
described below.
We aimed to recruit 90 participants who were aged ≥50 
years with a unilateral transtibial amputation for ≥1 year 
due to vascular, neurological or life- limiting reasons, who 
were categorised as having ‘limited community mobility’, 
with a stable residuum, and using a non- self- aligning 
prosthetic ankle- foot (eg, SACH, uniaxial, multiaxial (eg, 
multiflex) or other K1/K2 feet). We excluded anyone 
who had a contraindication to wearing their current 
prosthesis or the self- aligning ankle- foot (according to 
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the manufacturer’s specifications), had experienced a 
recent cerebrovascular event or had a disease affecting 
their memory. Allowing for 20% attrition, we anticipated 
72 participants in our final analysis.
Recruitment and randomisation
We used a two- stage screening process to identify eligible 
patients; full details are provided in the published 
protocol.16 In summary, potential participants were iden-
tified by database screening or during routine appoint-
ments to five prosthetics centres in England from July 
2018 to August 2019. They were posted a study invitation 
pack and asked to return a Consent to Contact form if 
they were interested in being contacted about the trial. A 
member of their multidisciplinary team then contacted 
them and completed the first section of the Screening 
Form over the telephone. If potentially eligible, they were 
invited into clinic to complete the outstanding screening 
questions, which had to be done face to face, and 
provide their written consent. Following consent, eligible 
patients completed all baseline measures before being 
randomised into one of two trial arms: keep their non- 
self- aligning prosthetic ankle- foot (standard treatment 
group) or receive a new self- aligning ankle- foot (interven-
tion group). Participants were randomised individually, 
stratified according to prosthetics centre on a 1:1 basis, by 
a telephone randomisation service set up by York Trials 
Unit. Blinding of the participants and investigators was 
not possible because of the nature of the intervention.
Standard treatment and intervention
Participants in the standard treatment group continued 
using their normal prosthetic ankle- foot and had access 
to all clinical services as normal. They were asked to carry 
on with their normal daily routine during the interven-
tion period.
Participants in the intervention group were fitted 
with the self- aligning prosthetic ankle- foot by their 
regular prosthetist. The self- aligning ankle- foot used in 
this trial was the AvalonK2, manufactured by Blatchford, 
Basingstoke, UK (Patent reg: 5336386), which was already 
commercially available and could be prescribed under the 
national health Service (NHS). Once fitted, participants 
were asked to ambulate with it, as they would normally 
with any new prosthetic ankle- foot for approximately 12 
weeks after fitting (intervention period). At the end of 
the study, participants in the intervention group only 
could keep the self- aligning ankle- foot if they preferred 
it. Participants in standard treatment group were not 
offered the self- aligning ankle- foot at the end of the study 
as it is not known whether it is better or more acceptable 
to users than the standard prosthesis.
Outcome measures
The primary outcome of this feasibility study related to 
collecting data on recruitment, consent and retention 
rates. Reasons for non- participation or withdrawal were 
recorded where possible. We assessed the completeness 
of data across multiple time points: baseline, interim 
and final follow- ups. The baseline and final assessments 
were conducted at the participant’s usual prosthetics 
centre. At the interim follow- up, only questionnaire data 
were collected via post. Data were gathered from ques-
tionnaires (baseline demographics and bespoke health 
resource use questionnaires, the Locomotor Capabilities 
Index (LCI-5),17 Houghton Scale,18 the Patient- Reported 
Outcomes Measurement Information System (PROMIS) 
Short- Form V.1.0 Pain (3a and 8a) questionnaires19 and 
EQ- 5D- 5L20 and from clinical assessments (Timed Up and 
Go (TUG) test,21 Timed Up and Down Stairs (TUDS) 
test,22 2 min walk test (2mWT)23 and Berg Balance Scale 
(BBS).24 Data related to daily step count and time spent 
walking were collected from a loaned activity monitor 
(activPAL4, PAL Technologies, Glasgow, UK) worn on the 
prosthesis for 1 week. At baseline, all participants wore 
their normal (non- self- aligning) prosthetic ankle- foot 
during the clinical assessments and activity monitor data 
collection; at final follow- up they wore whichever pros-
thetic ankle- foot they were using currently. AEs related 
to the prosthesis only, and any serious AEs (SAEs), were 
recorded throughout the study.
Statistical analyses
The recruitment rate was reported monthly, and overall, 
by site. An average monthly recruitment rate was calcu-
lated, with a 95% CI estimated from the data collected. 
The number of eligible patients and those approached 
for consent was summarised overall, by site, using counts 
and percentages.
Baseline data were summarised by trial arm, as 
randomised, with no formal comparison between the 
groups. Continuous data were reported descriptively and 
categorical data by counts and percentages. Completion 
rates of all the clinical outcome measures were reported 
by trial arm and overall.
Health economic analysis
The health economics work investigated the feasibility 
of collecting self- reported patient use of health service 
resources (eg, primary care visits, prescription medica-
tion) over the study period and to evaluate the appro-
priateness of these data. This information would help to 
refine the bespoke questionnaire in a future trial. A full 
cost- effectiveness analysis was not completed as this was 
a feasibility study. Nonetheless, the costing approach was 
undertaken from an NHS perspective; unit costs were 
derived from established national costing sources such 
as NHS Reference Costs25 and Personal Social Services 




Over 880 potential participants were initially screened 
by searching patient databases across the five prosthetics 
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centres. Seventy- eight were identified as potentially 
eligible after the first screening, but 12 were subse-
quently excluded following the final, second screening. 
Eighty- six per cent of those screened, who were found 
to be fully eligible, consented to participating (55 of 64 
participants) in the trial. The denominator was 64 as two 
were randomised in error and subsequently withdrawn 
(figure 1). As we used a two- stage screening process, 
only potential participants who met the initial inclusion 
criteria were approached; those uninterested in being 
involved during the initial screening were not screened 
further. Therefore, the consent rate may be artificially 
high. Reasons for non- participation are also presented in 
figure 1. In total, 55 participants (61% of the target 90 
participants) were included and randomised as follows: 
27 to the self- aligning prosthetic ankle- foot (interven-
tion) group and 28 to the non- self- aligning (standard 
treatment) group.
Initial recruitment was slower than anticipated, there-
fore, two additional recruiting sites were included 
midway through the trial, bringing the total number of 
participating sites to five. The average recruitment rate 
was 1.25 participants/site/month (95% CI 0.39 to 2.1) 
ranging from 0.83 to 2.2 participants per month. Each 
site recruited approximately the same number of partici-
pants (mean=11, range=9–13 participants), despite them 
being open to recruitment for different lengths of time 
(range=5.0–13.7 months).
Participants
The mean (SD) age of participants in this study was 68.8 
(9.6) years, ranging from 51.8 to 86.8 years. Most partici-
pants were male (85.5%) and all classified themselves as 
White British, Irish or other. The most common reason 
for amputation was diabetes (45.5%). Full participant 
characteristics are described in table 1 .
Follow-up and AEs
In addition to the two people randomised in error and 
withdrawn, a further two participants who were allocated 
to the intervention group withdrew from the study: one as 
a result of having suffered a stroke and one reported the 
self- aligning prosthetic ankle- foot was too heavy. At final 
follow- up, 51 of the 55 participants returned the question-
naires giving a retention rate of 93%. This was 71% of 
the planned target of 72 participants included in the final 
analysis.
A total of four SAEs and one AE were reported. The 
SAEs were due to the following reasons: stroke; fall 
and femoral fracture when not wearing their pros-
thesis (both of these cases occurred in the intervention 
group); fall and hip fracture, leading to hospitalisation 
and subsequently death; and recurrent falls with fibular 
fracture (both of these cases were in the standard treat-
ment group). The AE occurred because one participant 
(intervention group) developed blistering on their 
residuum.
Data completeness
There were four standardised measures completed at 
all three time points: LCI-5, Houghton, PROMIS 3a and 
PROMIS 8a. The average completion rate across all time 
points ranged from 89% to 94%. Data from four clin-
ical assessments (TUG, TUDS, 2mWT and BBS), and an 
activity monitor worn for a week, were collected at both 
baseline and final follow- up, and their average comple-
tion rate ranged from 92% to 95%. All the measures 
were well completed, or attempted, with at least 75% 
completed in full. Details of the outcome measures and 
completion rates can be found in tables 2 and 3.
None of the four standardised measures appeared to 
show a change between baseline and follow- up. For the 
2mWT, participants with the self- aligning prosthetic 
ankle- foot walked on average further at final follow- up 
(mean (SD): 88.8 (40.0) m) than at baseline (81.0 (31.4) 
m). This equates to an average increase of 6.2 (16.2) m in 
walking distance for the participants in the intervention 
group between these two time points. However, in the 
standard treatment group, there was an average decrease 
of 9.0 (29.8) m, indicating that these participants were 
walking less distance over 2 min at the final follow- up. 
Scores for the TUG, TUDS and BBS remained largely 
unchanged across both groups. Activity monitor data 
revealed that the daily time spent stepping between base-
line and follow- up was mostly unchanged for both groups, 
which was approximately 30 min per day. Conversely, the 
number of steps taken per day decreased in the interven-
tion group (1755.5 (1963.7) steps at baseline vs 1673.2 
(1594.4) steps at final follow- up) yet increased in the stan-
dard treatment group (1750.9 (1369.9) steps at baseline 
vs 1836.1 (1647.8) steps at final follow- up). The average 
change in number of steps taken per day decreased by 2.9 
(756.2) steps in the intervention group between baseline 
and final follow- up, yet increased by 283.3 (1614.8) steps 
in the standard treatment group. In both groups, the vari-
ability in daily stepping was high.
Health economic data
The health economic outcomes are based on the patient- 
completed questionnaires, which incorporated the 
EQ- 5D- 5L and a bespoke resource use questionnaire. The 
average completion rates were 93% and 63%, respectively. 
Over 89% of participants completed the EQ- 5D- 5L fully. 
At baseline, responses to the EQ- 5D- 5L indicated rela-
tively equal levels of health utility between the trial arms. 
By final follow- up, an increase in mean utility of 0.13 in 
the intervention group was observed, while mean utility 
in the standard treatment group remained the same. A 
positive mean difference in favour of the self- aligning 
prosthetic ankle- foot in the intervention group remained 
consistent after adjusting for baseline utility (table 4).
For the resource use questionnaire, the completion rates 
did not differ by the respective components, suggesting 
all sections were acceptable and each type of data was 
feasible to collect. Resource use was minimal across both 
primary and secondary/tertiary care for participants in 
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Figure 1 Consort flow chart for the STEPFORWARD study. LCI-5, Locomotor Capabilities Index; PROMIS, Patient- Reported 
Outcomes Measurement Information System; TUDS, Timed Up and Down Stairs; TUG, Timed Up and Go.
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Table 1 Demographic characteristics according to trial arm
Self- aligning (n=27) Standard (n=28) Overall (n=55)
Age, years n=27 n=28 n=55
  Mean (SD) 70.0 (9.2) 67.6 (10.0) 68.8 (9.6)
  Median (min, max) 71.5 (52.7, 86.8) 68.3 (51.8, 84.5) 70.7 (51.8, 86.8)
Gender, n(%)
  Male 23 (85.2) 24 (85.7) 47 (85.5)
  Female 4 (14.8) 4 (14.3) 8 (14.6)
Ethnicity, n(%)
  White (British, Irish or Other) 27 (100.0) 28 (100.0) 55 (100.0)
  Black (African, Caribbean or Other) 0 (0.0) 0 (0.0) 0 (0.0)
  Asian (Indian, Pakistani, Bangladeshi or Other) 0 (0.0) 0 (0.0) 0 (0.0)
  Mixed Background 0 (0.0) 0 (0.0) 0 (0.0)
  Chinese 0 (0.0) 0 (0.0) 0 (0.0)
Marital status, n(%)
  Living alone never married 2 (7.4) 3 (10.7) 5 (9.1)
  Living with partner 4 (14.8) 0 (0.0) 4 (7.3)
  Married/civil partnership 9 (33.3) 19 (67.9) 28 (50.9)
  Separated 2 (7.4) 1 (3.6) 3 (5.5)
  Divorced 5 (18.5) 4 (14.3) 9 (16.4)
  Widowed 2 (7.4) 1 (3.6) 3 (5.5)
  Missing 3 (11.1) 0 (0.0) 3 (5.5)
Main activity, n(%)
  Full- time employment 1 (3.7) 3 (10.7) 4 (7.3)
  Part- time employment 0 (0.0) 1 (3.6) 1 (1.8)
  Self- employed 0 (0.0) 0 (0.0) 0 (0.0)
  Unable to work due to poor health 1 (3.7) 5 (17.9) 6 (10.9)
  Unemployed 0 (0.0) 1 (3.6) 1 (1.8)
  Retired 24 (88.9) 17 (60.7) 41 (74.6)
  Other 1 (3.7) 1 (3.6) 2 (3.6)
Smoking status, n(%)
  Ex- smoker 15 (55.6) 17 (60.7) 32 (58.2)
  Current smoker 1 (3.7) 3 (10.7) 4 (7.3)
  Never smoked 11 (40.7) 8 (28.6) 19 (34.6)
Diabetes status, n(%)
  Yes 19 (70.4) 18 (64.3) 37 (67.3)
  No 8 (29.6) 10 (35.7) 18 (32.7)
If yes:
  Type one 5 (26.3) 2 (11.1) 7 (18.9)
  Type two 12 (63.2) 13 (72.2) 25 (67.8)
  Missing 2 (10.5) 3 (16.7) 5 (13.5)
Cause of amputation, n(%)a
  Diabetes 14 (51.9) 11 (39.3) 25 (45.5)
  Peripheral vascular disease 10 (37.0) 10 (35.7) 20 (36.4)
  Blood clot 3 (11.1) 2 (7.1) 5 (9.1)
  Deep vein thrombosis 1 (3.7) 0 (0.0) 1 (1.8)
  Aneurysm 0 (0.0) 1 (3.6) 1 (1.8)
Continued
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both arms of the trial. The most frequently received care 
was via outpatient attendances at NHS hospitals (mean 
(SD): 0.21 (0.51) rising to 2.04 (3.72) visits from baseline 
to final follow- up for the intervention group; 0.08 (0.27) 
rising to 1.14 (2.19) visits for the standard treatment 
group.
Medications were grouped according to comor-
bidity to investigate their inclusion in a full- scale trial 
as follows: blood pressure/heart problems, neuropathic 
pain, diabetes, phantom pain. Participant uptake of the 
groups of medications explored using the resource use 
questionnaire was high, and there were some differences 
between groups, suggesting a micro- costing exercise 
including medications data may be merited in a full- 
scale trial. Approximately 73% of participants overall 
reported taking medications related to blood pressure 
and/or heart problems, and 62% of participants overall 
took medications for diabetes. Medication use appeared 
to increase over the course of the trial for participants in 
both arms.
The intervention (self- aligning prosthetic ankle- 
foot) was delivered in the NHS setting by the usual staff 
providing post- amputation aftercare (prosthetist, physio-
therapist). Other than the self- aligning ankle- foot itself, 
participants received equal care to standard treatment. 
The cost (at 2020 UK prices) of the self- aligning ankle- 
foot used in the trial was £1192 compared with the non- 
self- aligning version estimated at £287 (although this 
depends on the exact standard ankle- foot and would 
need to be determined accurately based on the user’s 
actual foot). The additional intervention cost to the NHS 
of delivering the self- aligning ankle- foot is therefore 
approximately £905.
Identification of primary outcome measure
The findings from this study have demonstrated feasibility, 
acceptability and a signal of efficacy for three measures: 
walking ability with the 2mWT, daily activity with activity 
monitor data and quality of life with the EQ- 5D- 5L. We 
consulted with our patient advisory group (PAG) to inform 
the appropriateness of a primary outcome to be used in 
a future full- scale trial. The PAG members reported that, 
of the three measures, the EQ- 5D- 5L resonated most 
strongly with them as it captured the constructs that were 
important to them (eg, mobility, pain, usual activities, 
general health). This measure will be considered for use 
as the primary outcome in a future trial.
DISCUSSION
Main findings
The primary objective of this study was to determine 
the feasibility of conducting a future, full- scale RCT of 
the effectiveness and cost- effectiveness of a self- aligning 
prosthetic ankle- foot compared with a standard pros-
thetic ankle- foot. There are few clinical trials involving 
older adults living with a lower limb amputation, who 
are an under- researched but growing group of patients. 
The consent, retention and completion rates were high, 
demonstrating that it is feasible to recruit and retain 
participants to a future trial addressing the research ques-
tion. While the consent rate may be artificially high, due 
to screening methods used in the current study, the final 
retention and completion rates indicate the study was 
acceptable to participants.
We did not meet the recruitment target of 90. Given 
that only 7.4% of screened patients met the eligibility 
criteria (though only 7.2% were truly eligible, due to 
the randomisation in error), it is important to consider 
whether the criteria were too restrictive and should be 
adjusted in a future trial. It is common that the residuum 
undergoes considerable volume changes within the first 
year post- amputation, necessitating the fabrication of 
new prosthetic sockets. As the intervention period of this 
feasibility study was only 12 weeks long (due to resource 
constraints), we sought to recruit established prosthesis 
users who had no current contraindications to wearing 
their ankle- foot prosthesis, had a stable residuum volume 
and the same prosthetic socket for ≥3 months and were 
free of open wounds or infections on the residuum. We 
also only included patients who had a transtibial amputa-
tion secondary to a health condition, as this group is most 
likely categorised as having ‘limited community mobility’ 
and frequently prescribed a non- self- aligning prosthetic 
ankle- foot. It would be clinically relevant to broaden the 
eligibility criteria to include any patient with a transtibial 
amputation within this mobility category, regardless of 
cause and time since amputation, in a future study. This 
would widen the pool of patients potentially eligible for 
the trial. However, we do not have data from the feasi-
bility study to assess impact on recruitment and it would 
be important for the future trial to have an internal pilot 
with clear stop- go criteria to confirm the feasibility of a 
modified study design.
Five AEs, of which four were categorised as serious, 
occurred throughout this trial. All of the SAEs (one 
Self- aligning (n=27) Standard (n=28) Overall (n=55)
  Diabetic neuropathy 2 (7.4) 1 (3.6) 3 (5.5)
  Other neuropathy 1 (3.7) 0 (0.0) 1 (1.8)
  Cancer 1 (3.7) 1 (3.6) 2 (3.6)
  Other 5 (18.5) 6 (21.4) 11 (20.0)
Table 1 Continued
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Table 2 Standard outcomes at each time point (baseline, interim and final follow- up), by trial arm and overall
Self- aligning (n=27) Standard (n=28) Overall (n=55)
LCI-5 overall score (0–56): average completion 94%
  Baseline N=25 N=28 N=53
  Mean (SD) 36.4 (12.0) 39.6 (11.2) 39.1 (11.6)
  Median (p25, p75) 38 (30.3, 46) 38 (31, 50) 38 (30.3, 47)
  Interim N=24 N=25 N=49
  Mean (SD) 37.3 (12.3) 38.5 (10.8) 37.9 (11.4)
  Median (p25, p75) 39.5 (28.5, 47.5) 41 (30, 44.7) 41 (29, 46)
  Final N=25 N=26 N=51
  Mean (SD) 37.8 (11.4) 39.2 (11.2) 38.5 (11.2)
  Median (p25, p75) 40 (30, 47) 40.5 (29, 49) 40 (29, 47)
Houghton overall score (0–12): average completion: 89%
  Baseline N=24 N=28 N=52
  Mean (SD) 7.8 (2.0) 8.8 (1.8) 8.3 (1.9)
  Median (p25, p75) 8 (7.5, 9) 9 (8, 10) 9 (8, 9)
  Interim N=20 N=23 N=43
  Mean (SD) 8.4 (2.0) 8.5 (1.3) 8.5 (1.6)
  Median (p25, p75) 9 (7, 10) 9 (8, 9) 9 (8, 10)
  Final N=23 N=26 N=49
  Mean (SD) 8.3 (1.9) 8.5 (2.0) 8.4 (1.9)
  Median (p25, p75) 8 (8, 10) 9 (8, 9) 9 (8, 9)
PROMIS 3a overall score (30.7–71.8): average completion: 90%
  Baseline N=27 N=27 N=54
  Mean (SD) 41.3 (10.0) 43.1 (9.5) 42.2 (9.7)
  Median (p25, p75) 43.5 (30.7, 52.1) 43.5 (30.7, 49.4) 43.5 (30.7, 49.4)
  Interim N=21 N=25 N=46
  Mean (SD) 43.6 (9.6) 45.6 (10.3) 44.7 (10.0)
  Median (p25, p75) 43.5 (30.7, 49.4) 46.3 (40.2, 52.1) 46.3 (30.7, 52.1)
  Final N=24 N=22 N=46
  Mean (SD) 40.4 (9.4) 42.7 (8.7) 41.4 (9.0)
  Median (p25, p75) 40.2 (30.7, 47.9) 44.9 (30.7, 49.4) 43.5 (30.7, 49.4)
PROMIS 8a overall score (40.7–77.0): average completion: 94%
  Baseline N=27 N=28 N=55
  Mean (SD) 52.8 (11.2) 51.7 (9.4) 52.2 (10.2)
  Median (p25, p75) 55 (40.7, 63.5) 51.8 (40.7, 58.5) 52.3 (40.7, 60.2)
  Interim N=23 N=24 N=47
  Mean (SD) 53.5 (11.3) 56.7 (8.9) 55.1 (10.1)
  Median (p25, p75) 55 (40.7, 64.1) 58.8 (52.3, 63.2) 57.4 (40.7, 63.5)
  Final N=25 N=26 N=51
  Mean (SD) 51.2 (11.4) 53.3 (10.0) 52.3 (10.7)
  Median (p25, p75) 49.9 (40.7, 60.2) 54.5 (40.7, 60.2) 53.2 (40.7, 60.2)
LCI-5: higher scores indicate a greater locomotor capability with the prosthesis; Houghton: higher scores indicate greater performance and 
comfort; PROMIS 3a (pain intensity): coverts raw scores to T- scores, higher scores indicate more intense pain; PROMIS 8a: higher scores 
indicate more pain interference.
LCI-5, Locomotor Capabilities Index; PROMIS, Patient- Reported Outcomes Measurement Information System.
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Table 3 Clinical assessments (TUG, TUDS, 2mWT and BBS) at baseline and final follow- up, by trial arm and overall
Self- aligning (n=27) Standard (n=28) Overall (n=55)
TUG, seconds: average completion 95%
  Baseline N=27 N=28 N=55
  Mean (SD) 20.8 (15.2) 21.3 (23.5) 21.1 (19.7)
  Median (p25, p75) 17 (12, 24) 14.5 (11.5, 23) 17 (12, 23)
  Unable to complete 0 0 0
  Final N=23 N=22 N=45
  Mean (SD) 21.0 (19.1) 17.8 (8.4) 19.5 (14.8)
  Median (p25, p75) 16 (11, 13) 14.5 (13, 22) 15 (11, 23)
  Unable to complete 0 2 0
TUDS, seconds: average completion 93%
  Baseline N=17 N=27 N=44
  Mean (SD) 61.4 (33.0) 66.9 (38.5) 64.7 (36.2)
  Median (p25, p75) 50 (39, 72) 51 (41, 88) 50.5 (41, 88)
  Unable to complete 9 1 10
  Final N=19 N=21 N=40
  Mean (SD) 59.2 (29.2) 68.1 (56.7) 63.9 (45.4)
  Median (p25, p75) 51 (33, 79) 48 (39, 74) 48.5 (38, 76.5)
  Unable to complete: 4 3 7
2mWT, metres: average completion 95%
  Baseline N=27 N=28 N=55
  Mean (SD) 81.0 (31.4) 94.7 (33.5) 87.9 (33.5)
  Median (p25, p75) 77 (60, 110) 95 (68, 113) 83 (61, 113)
  Final N=23 N=24 N=47
  Mean (SD) 88.8 (40.0) 83.9 (41.5) 86.3 (39.5)
  Median (p25, p75) 80 (62, 120) 80 (57.5, 106) 80 (60, 108)
BBS, scored 0–56: average completion 92%
  Baseline N=26 N=27 N=53
  Mean (SD) 39.5 (11.3) 42.9 (8.1) 41.3 (9.8)
  Median (p25, p75) 41.5 (32, 48) 43 (36, 51) 43 (34, 48)
  Final N=22 N=24 N=46
  Mean (SD) 40.7 (12.9) 39.4 (11.6) 40.0 (12.1)
  Median (p25, p75) 44 (30, 51) 41.5 (33, 49) 41.5 (33, 50)
Activity monitor: minutes stepping per day
  Baseline N=26 N=27 N=53
  Mean (SD) 29.9 (30.8) 31.1 (24.9) 30.5 (27.7)
  Median (p25, p75) 24.7 (9.4, 31.4) 26 (14.5, 40.3) 25.9 (10.6, 34.1)
  Final N=22 N=25 N=47
  Mean (SD) 27.7 (24.0) 31.2 (25.8) 29.6 (24.8)
  Median (p25, p75) 24.1 (3.6, 45.0) 25.9 (17.3, 31.1) 25.7 (10.6, 40.3)
Activity monitor: steps taken per day
  Baseline N=26 N=27 N=53
  Mean (SD) 1755.5 (1963.7) 1750.9 (1369.6) 1753.2 (1670.9)
  Median (p25, p75) 1292.3 (587.1, 1835.7) 1572.9 (802.3, 2234.6) 1448.6 (654.6, 2144.0)
  Final N=22 N=25 N=47
  Mean (SD) 1673.2 (1594.4) 1836.1 (1647.8) 1759.9 (1607.4)
Continued
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stroke and three falls) were not deemed related to the 
self- aligning prosthetic ankle- foot. This clinical group is 
vulnerable to falling, with one recent study stating that 
over 57% of community- living lower limb prosthesis users 
fall at least once a year27 and that 36%–75% of fallers 
experience recurrent falls.27 28 The participant who devel-
oped blistering on the residuum (the one AE) had been 
allocated to the intervention group. It is not uncommon 
for blistering to occur if the skin on the residuum is 
subjected to increased friction as a result of wearing the 
prosthesis for longer. In most instances, blisters heal rela-
tively quickly, and the prosthesis user can soon return to 
normal function with their prosthesis.
Results in context with other research
A few randomised trials of several different prosthetic 
ankle- feet (although not self- aligning), evaluating func-
tion and self- report measures, have been conducted 
previously.29–31 Some of these studies lacked sample size 
calculations and presented small samples (range n=10–27 
participants/trial). Moreover, they represented a hetero-
geneous group in terms of their mobility level classifica-
tions (participants were mostly categorised as ‘unlimited 
community ambulators’ (K3) or ‘active adults’ (K4)), 
cause of amputation and health comorbidities. The age 
of the participants in these studies was also younger than 
in the current feasibility trial (mean range 42.3–57 years). 
Therefore, the findings from existing studies are difficult 
to generalise to the majority of people with a lower limb 
amputation due to dysvascularity, in the UK and other 
developed nations. We are not aware of any randomised 
trials investigating prosthetic ankle- feet uniquely involving 
older adults classified as having ‘limited community 
mobility’ as a result of health- related issues.
Outcome measures
This study was not designed to assess the effectiveness 
of the self- aligning prosthetic ankle- foot, and no formal 
comparisons between randomised groups were under-
taken as the study was not powered to report effects. Three 
measures indicated a signal of potential efficacy including 
the 2mWT (walking ability), daily activity as measured 
with activity monitors, and quality of life as measured with 
the EQ- 5D- 5L. Conversely, other measures (including 
some population- specific measures and common clinical 
assessments) did not indicate any difference.
We demonstrated that the use of activity monitors, and 
their implementation using postal delivery, was feasible 
in this patient group. We believe this was supported by 
our study procedures, which included regular partici-
pant information letters alerting them to the next stages 
of the trial, and a detailed bespoke leaflet explaining 
how participants were requested to fit the activity 
monitor onto the prosthesis themselves. As the monitor 
was affixed to the prosthesis, there were few issues with 
discomfort or discontinued use. Trials using subjective 
outcomes, where the outcome measure is self- reported 
by a participant or assessment of an event requires exer-
cise of judgement by an observer, may overestimate the 
treatment effect.32 Therefore, it was important to estab-
lish the feasibility of using this more objective outcome 
in a future trial.
On average, both groups took fewer than 1800 daily 
steps over 30 min throughout the day. The data related 
to daily steps and stepping time reinforced the largely 
sedentary behaviour experienced by this clinical group. 
Our findings are broadly similar to a previous study 
that reported an average of 1450 (SD 1309) steps/day 
in a group of older individuals (age: 64 (SD 9) years) 
with a predominantly transtibial amputation (95% of 
total participants) as a result of vascular disease when 
measured over 10 days.33 Further research is warranted 
to ascertain whether a more functional prosthetic ankle- 
foot, compared with current standard care with a non- 
self- aligning ankle- foot, has the long- term potential to 
Self- aligning (n=27) Standard (n=28) Overall (n=55)
  Median (p25, p75) 1356.4 (204.0, 2719.4) 1510.3 (922.9, 1908.0) 1446.3 (551.4, 2270.0)
TUG and TUDS: faster time indicates better performance; 2mWT: further distance indicates better walking ability; BBS: higher score indicates 
better balance.
BBS, Berg Balance Scale; 2mWT, 2 min walk test; TUDS, Timed Up and Down Stairs; TUG, Timed Up and Go.
Table 3 Continued
Table 4 EQ- 5D- 5L mean (SD) utility scores, unadjusted mean difference (95% CI) and adjusted for baseline utility at each time 





Unadjusted difference (self- 
aligning vs standard) (95% CI)
Adjusted difference (self- 
aligning vs standard) (95% CI)
EQ- 5D- 5L (average completion 93%)
Baseline 0.62 (0.30) 0.63 (0.35) −0.009 (−0.188 to 0.169) −0.009 (−0.188 to 0.169)
Interim 0.64 (0.18) 0.57 (0.24) 0.067 (−0.055 to 0.189) 0.104 (0.001 to 0.207)
Final 0.75 (0.16) 0.63 (0.32) 0.120 (−0.021 to 0.262) 0.117 (0.017 to 0.216)
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increase daily stepping, which could have important 
implications for patient benefit.
Health economics
It was feasible to collect the data required for a full- scale 
trial economic evaluation from this patient population. 
The high levels of completion suggest acceptability of 
instruments. The EQ- 5D- 5L is likely to be sensitive to 
changes in health states over time. Some changes to the 
bespoke health resource use questionnaire could be made 
in future. Use of privately funded healthcare services was 
negligible so this section could potentially be omitted in a 
full- scale trial. Participant uptake of the medications in the 
resource use questionnaire was high and there were some 
differences between groups suggesting a microcosting 
exercise including medications data may be merited in 
a full- scale trial. Although no resource use of walking 
aids, adaptations and accessories had an uptake greater 
than 20%, participants were established prosthesis users 
who may have already accessed the required adaptations 
prior to entering the trial. Therefore, if a future trial had 
broader eligibility criteria to include unestablished pros-
thesis users, it may be important to retain this item.
The approximate NHS cost of the intervention is ~£900 
above current standard care as it is assumed that the self- 
aligning prosthetic ankle- foot is delivered in the usual 
NHS setting and by the usual staff. There are various self- 
aligning prosthetic ankle- feet available commercially (eg, 
using hydraulic mechanisms vs micro- processor controlled 
and with actively powered propulsion), at varying costs 
and suitability (eg, some prosthetic ankle- feet are heavier 
and more suitable for different patient needs). At the 
present time, we have only considered a single prosthetic 
ankle- foot, but one that is designed for our clinical popu-
lation of interest. A full health economics evaluation, as 
part of full- scale trial, would be able to evaluate whether 
the initial higher cost of the ankle- foot could be offset by 
reduced use of other health resources (eg, medications, 
prosthetic adjustments) and/or increased patient quality 
of life.
Strengths and weaknesses
Prosthetics services are an under- researched area within 
the NHS. As this was one of few clinical trials conducted in 
this area in the UK, we now have a better understanding 
of the challenges of recruiting in this setting, such as the 
limited research resources at clinical sites and variation 
in how sites organise their patient database systems. The 
recruiting sites in England provided a wide geograph-
ical spread (North East, North West, East of England, 
Midlands and South of England); however, the partici-
pants recruited across these sites were homogeneous in 
their ethnicity (self- reported as White British, Irish or 
other). In future, we will develop strategies to maximise 
participation from patients across different ethnic groups 
and nations in the UK.
The majority of participants were recruited after a 
member of their clinical team screened the patient 
database for potentially eligible participants and posted 
them a study invitation pack. Therefore, the majority 
of the screening forms (79%) were initially completed 
over the phone before the face- to- face screening process 
confirmed their final eligibility. A limitation of this 
feasibility study was our lack of prior knowledge of the 
management of patient databases, which varied across the 
sites. Four sites used an electronic database for patient 
records while one used a paper- based system only; one 
of these sites used three different patient record systems. 
Not all patient records were up to date, resulting in two 
participants being randomised in error because they did 
not fulfil the inclusion criteria fully, and they were subse-
quently withdrawn. In a future trial, it will be essential 
to gather relevant information about the organisation 
of patient records at the local participating sites prior to 
opening that site to facilitate effective recruitment. This 
would also help sites recruit participants more consis-
tently across the recruitment period. We were concerned 
at the outset about the risk of ‘resentful demoralisation’ 
among participants allocated to usual care and were 
mindful of this in developing the patient information for 
the study. The fact that adherence to the study processes 
and completion of outcome measures were similar 
across groups provides some reassurance in this regard. 
However, this would need continuing attention in the 
design of a full- scale trial.
Future research
Based on the findings from this feasibility study, we 
propose some adaptations to the study protocol for a 
future full- scale trial. They include:
 ► Broadening the participant eligibility criteria to 
include new patients with a transtibial amputation, 
who would be categorised as having ‘limited commu-
nity mobility’ by their multidisciplinary team, and 
therefore, likely to receive a non- self- aligning pros-
thetic ankle- foot.
 ► Lengthening the intervention period of accommo-
dating to the self- aligning ankle- foot, and including 
a longer follow- up period, would be important for 
unestablished prosthesis users if the criteria were 
more inclusive in a full- scale trial.
 ► Refining the screening process to screen more poten-
tially eligible participants, even if some prove ineli-
gible afterwards, with advanced information about 
site patient databases.
 ► Reviewing the secondary outcome measures.
 ► Redesigning some aspects of the health resource use 
questionnaire.
 ► Approaching other prosthetics centres nationally to 
explore their willingness to be involved in a full- scale 
trial.
CONCLUSION
Although we did not reach our target sample, due to 
slower than anticipated recruitment, 71% of expected 
participants were in the final analysis, owing to our 
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retention rate of 93%. Therefore, we believe the STEP-
FORWARD study demonstrated feasibility to recruit and 
retain participants and the ability to obtain a variety of 
complete datasets collected in clinic and via post. We 
have also evidenced the ability to deliver the trial across 
multiple prosthetics centres in England. The knowl-
edge gained and lessons learnt can be implemented in a 
future definitive trial to determine the effectiveness and 
cost- effectiveness of a self- aligning prosthetic ankle- foot 
compared with a non- self- aligning version for people 
with a transtibial amputation and categorised as having 
‘limited community mobility’.
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